Ligand Invests in Dianomi Therapeutics

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with its $3 million investment in Dianomi Therapeutics, Inc., a biopharmaceutical company focused on improving the delivery and efficacy of large and small molecules in the treatment of a variety of diseases and on therapies for inflammatory diseases. Read the press release.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines.

San Diego-based Hayden Trubitt and Amit Singh represented Ligand in this transaction.

Please enable JavaScript, then refresh this page. JavaScript is required on this site.